TY - JOUR
T1 - The 'Wise List'- A Comprehensive Concept to Select, Communicate and Achieve Adherence to Recommendations of Essential Drugs in Ambulatory Care in Stockholm
AU - Gustafsson, Lars L.
AU - Wettermark, Björn
AU - Godman, Brian
AU - Andersén-Karlsson, Eva
AU - Bergman, Ulf
AU - Hasselström, Jan
AU - Hensjö, Lars Olof
AU - Hjemdahl, Paul
AU - Jägre, Ingrid
AU - Julander, Margaretha
AU - Ringertz, Bo
AU - Schmidt, Daniel
AU - Sjöberg, Susan
AU - Sjöqvist, Folke
AU - Stiller, Carl Olav
AU - Törnqvist, Elisabeth
AU - Tryselius, Rolf
AU - Vitols, Sigurd
AU - Von Bahr, Christer
PY - 2011/4
Y1 - 2011/4
N2 - The aim was to present and evaluate the impact of a comprehensive strategy over 10years to select, communicate and achieve adherence to essential drug recommendations (EDR) in ambulatory care in a metropolitan healthcare region. EDRs were issued and launched as a 'Wise List' by the regional Drug and Therapeutics Committee in Stockholm. This study presents the concept by: (i) documenting the process for selecting, communicating and monitoring the impact of the 'Wise List'; (ii) analysing the variation in the number of drug substances recommended between 2000 and 2010; (iii) assessing the attitudes to the 'Wise List' among prescribers and the public; (iv) evaluating the adherence to recommendations between 2003 and 2009. The 'Wise List' consistently contained 200 drug substances for treating common diseases. The drugs were selected based on their efficacy, safety, suitability and cost-effectiveness. The 'Wise List' was known among one-third of a surveyed sample of the public in 2002 after initial marketing campaigns. All surveyed prescribers knew about the concept and 81% found the recommendations trustworthy in 2005. Adherence to recommendations increased from 69% in 1999 to 77% in 2009. In primary care, adherence increased from 83% to 87% from 2003 to 2009. The coefficient of variation (CV%) decreased from 6.1% to 3.8% for 156 healthcare centres between these years. The acceptance of the 'Wise List' in terms of trust among physicians and among the public and increased adherence may be explained by clear criteria for drug recommendations, a comprehensive communication strategy, electronic access to recommendations, continuous medical education and involvement of professional networks and patients.
AB - The aim was to present and evaluate the impact of a comprehensive strategy over 10years to select, communicate and achieve adherence to essential drug recommendations (EDR) in ambulatory care in a metropolitan healthcare region. EDRs were issued and launched as a 'Wise List' by the regional Drug and Therapeutics Committee in Stockholm. This study presents the concept by: (i) documenting the process for selecting, communicating and monitoring the impact of the 'Wise List'; (ii) analysing the variation in the number of drug substances recommended between 2000 and 2010; (iii) assessing the attitudes to the 'Wise List' among prescribers and the public; (iv) evaluating the adherence to recommendations between 2003 and 2009. The 'Wise List' consistently contained 200 drug substances for treating common diseases. The drugs were selected based on their efficacy, safety, suitability and cost-effectiveness. The 'Wise List' was known among one-third of a surveyed sample of the public in 2002 after initial marketing campaigns. All surveyed prescribers knew about the concept and 81% found the recommendations trustworthy in 2005. Adherence to recommendations increased from 69% in 1999 to 77% in 2009. In primary care, adherence increased from 83% to 87% from 2003 to 2009. The coefficient of variation (CV%) decreased from 6.1% to 3.8% for 156 healthcare centres between these years. The acceptance of the 'Wise List' in terms of trust among physicians and among the public and increased adherence may be explained by clear criteria for drug recommendations, a comprehensive communication strategy, electronic access to recommendations, continuous medical education and involvement of professional networks and patients.
UR - http://www.scopus.com/inward/record.url?scp=79952776749&partnerID=8YFLogxK
U2 - 10.1111/j.1742-7843.2011.00682.x
DO - 10.1111/j.1742-7843.2011.00682.x
M3 - Article
C2 - 21414143
AN - SCOPUS:79952776749
SN - 1742-7835
VL - 108
SP - 224
EP - 233
JO - Basic and Clinical Pharmacology and Toxicology
JF - Basic and Clinical Pharmacology and Toxicology
IS - 4
ER -